Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.0
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 6, November-December, p. 1321–1330

doi: 10.17219/acem/65853

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Anetta Undas1,A,D,E, Tadeusz Góralczyk2,A,D,E

1 Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

2 John Paul II Hospital, Kraków, Poland


Direct oral anticoagulants (DOACs) or non-vitamin K oral anticoagulants (NOACs) are increasingly used in the prevention of recurrent venous thromboembolism (VTE), including that associated with thrombophilia. The efficacy of DOACs in thrombophilic patients, especially those with severe trombophilia or triple positive antiphospholipid syndrome (APS) with arterial thromboembolic events, remains controversial. Most case reports and case series indicate that DOACs are an attractive therapeutic option in the vast majority of these patients at high risk of recurrent VTE with more concerns raised in high-risk APS patients and these deficient in protein S (PS). Adherence to DOACs is of paramount importance in these patients. In this review we presented available data on the management of patients with thrombophilia using rivaroxaban, dabigatran or apixaban at standard doses. Moreover, we also demonstrated the overall effects of DOACs on coagulation tests, particularly those determined during thrombophilia screening such as lupus anticoagulant, antithrombin, protein C, PS, activated protein C ratio. Despite the paucity of data from randomized studies, the current evidence supports the use of DOACs in thrombophilia, especially those who prefer such treatment or have unstable anticoagulation with vitamin K antagonists or unacceptable adverse events while using these drugs.

Key words

thrombophilia, antiphospholipid syndrome, anticoagulant drugs

References (78)

  1. Kakkos SK, Kirkilesis GI, Tsolakis IA: Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: A systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 2014, 48, 565–575.
  2. Niewada M, Członkowska A: Prevention of ischemic stroke in clinical practice: A role of internists and general practitioners. Pol Arch Med Wewn 2014, 124, 540–548.
  3. Schaefer JK, McBane RD, Black DF: Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients. Thromb Haemost 2014, 112, 947–950.
  4. Win K, Rodgers GM: New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014, 89, 1017.
  5. Weitz JL, Jaffer IH: Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants. Pol Arch Med Wewn 2016 (in press).
  6. Dentali F, Cei M, Mumoli N, Gianni M: How to predict shortand long-term mortality in patients with pulmonary embolism? Pol Arch Med Wewn 2015, 125, 82–88.
  7. Rabinovich A, Kahn SR: How to predict and diagnose postthrombotic syndrome. Pol Arch Med Wewn 2014, 124, 410–416.
  8. Kyrle PA: Venous thrombosis: Who should be screened for thrombophilia in 2014? Pol Arch Med Wewn 2014, 124, 65–69.
  9. Montagnana M, Danese E, Lippi G: Genetic risk factors of atherothrombosis. Pol Arch Med Wewn 2014, 124, 474–482.
  10. Sciascia S, Lopez-Pedrera C, Cecchi I, Pecoraro C, Roccatello D, Cuadrado MJ: Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology (Oxford) 2016 (Epub ahead of print).
  11. Arachchillage DJ, Cohen H: Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013, 15, 331.
  12. Undas A, Pasierski T, Windyga J, Crowther M: Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn 2014, 124, 124–135.
  13. Patnaik MM, Moll S: Inherited antithrombin deficiency: A review. Haemophilia 2008, 14, 1229–1239.
  14. Manucci PM, Franchini M: Classic thrombophilic gene variants. Thromb Haemost 2015, 114, 885–889.
  15. Celinska-Lowenhoff M, Iwaniec T, Alhenc-Gelas M, Musial J, Undas A: Arterial and venous thrombosis and prothrombotic fibrin clot phenotype in a Polish family with type 1 antithrombin deficiency (antithrombin Krakow). Thromb Haemost 2011, 106, 379–381.
  16. Odnoczko E, Vertun-Baranowska B, Buczma A, Buczma A, Stefańska-Windyga E, Oldenburg J, Windyga J: Podłoże genetyczne wrodzonego niedoboru antytrombiny w 18 polskich rodzinach. Acta Haematol Pol 2011, 42, 519–524.
  17. Celinska-Löwenhoff M, Iwaniec T, Alhenc-Gelas M, Musial J, Undas A: Antithrombin Krakow II (c.624 + 1 G > T): A novel mutation leading to type 1 antithrombin deficiency. Blood Coagul Fibrinolysis 2012, 23, 454–455.
  18. Szymańska M, Alhenc-Gelas M, Undas A: Recurrent ischemic cerebrovascular events in a patient with type I antithrombin deficiency caused by 9788 G > A splice site mutation: A case report. Blood Coagul Fibrinolysis 2013, 24, 213–215.
  19. Szymańska M, Alhenc-Gelas M, Undas A: Antithrombin Rybnik: A new point mutation (nt 683 G > T) associated with type I antithrombin deficiency in a patient with venous thromboembolism and recurrent superficial venous thrombosis. Blood Coagul Fibrinolysis 2013, 24, 579–580.
  20. Cieśla M, Wypasek E, Corral J, Alhence-Gelas M, Undas A: Antithrombin Katowice: Exon 1 deletion in the SERPINC1 gene associated with type I antithrombin deficiency. Blood Coagul Fibrinolysis 2015, 26, 95–97.
  21. Franchini M, Veneri D, Salvagno GL: Inherited thrombophilia. Crit Rev Clin Lab Sci 2006, 43, 249–290.
  22. Joalland F, de Boysson H, Darnige L, Johnson A, Jeanjean C, Cheze S, Augustin A, Auzary C, Geffray L: Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: Learning from a difficult case report. Rev Med Interne 2014, 35, 752–756.
  23. Van Bruwaene L, Huisman A, Urbanus RT, Versluys B: Heparin-resistant thrombosis due to homozygous antithrombin deficiency treated with rivaroxaban: A case report. J Pediatr Hematol Oncol 2016 (in press).
  24. Whitlatch NL, Ortel TL: Thrombophilias: When should we test and how does it help? Semin Respir Crit Care Med 2008, 29, 25–39.
  25. Wypasek E, Pankiw-Bembenek O, Potaczek DP, Alhenc-Gelas M, Trebacz J, Undas A: A missense mutation G109R in the PROC gene associated with type I protein C deficiency in a young Polish man with acute myocardial infarction. Int J Cardiol 2013,167, 146–148.
  26. Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A: Novel missense mutation C106R in the PROC gene associated with type I protein C deficiency in a young Polish man with high-risk pulmonary embolism. Pol Arch Med Wewn 2014, 124, 75–76.
  27. Hermans C, Eeckhoudt S, Lambert C: Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost 2012, 107, 1189–1191.
  28. García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N: Molecular basis of protein S deficiency. Thromb Haemost 2007, 98, 543–556.
  29. Wypasek E, Alhenc-Gelas M, Undas A: First report of a large PROS1 deletion from exon 1 through 12 detected in Polish patients with deep-vein thrombosis. Thromb Res 2013, 132, 143–144.
  30. Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A: Heerlen polymorphism associated with type III protein S deficiency and factor V Leiden mutation in a Polish patient with deep vein thrombosis. Blood Coagul Fibrinolysis 2014, 25, 84–85.
  31. Wypasek E, Potaczek DP, Płonka J, Alhenc-Gelas M, Undas A: Protein S deficiency and Heerlen polymorphism in a Polish patient with acute myocardial infarction and previous venous thromboembolism. Thromb Res 2013, 132, 776–777.
  32. Martinelli I, Bucciarelli P, Artoni A, Fossali EF, Passamonti SM, Tripodi A, Peyvandi F: Anticoagulant treatment with rivaroxaban in severe protein S deficiency. Pediatrics 2013, 132, 1435–1439.
  33. Chighizola CB, Moia M, Meroni PL: New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 2014, 12, 1279–1282.
  34. Cook RM, Rondina MT, Horton DJ: Rivaroxaban for the long-term treatment of spontaneous ovarian vein thrombosis caused by Factor V Leiden homozygosity. Ann Pharmacother 2014, 48, 1055–1060.
  35. Li Calzi M, Placci A, Lina D, Grassi F, Paoli G, Bianconcini M,Cattabiani MA, Menozzi A: ST-segment elevation myocardial infarction in a patient with thrombophilia taking new oral anticoagulants. G Ital Cardiol (Rome) 2016, 17, 23–25.
  36. Pengo V, Denas G, Padayattil SJ, Zoppellaro G, Bison E, Banzato A, Hoxha A, Ruffatti A: Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn 2015, 125, 672–677.
  37. Arslan E, Demirbaş Ş, Aykan MB, Özgür G, Sağlam K: Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn 2015, 125, 785.
  38. Pengo V: Four good reasons to appreciate triple positivity. Pol Arch Med Wewn 2016, 126, 7–8.
  39. Zawilska K, Musiał J: Comment on “venous thrombosis: Who should be screened for thrombophilia in 2014?” Pol Arch Med Wewn 2014, 124, 215–216.
  40. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A: The use of rivaroxaban in patients with antipospholipid syndrome: A series of 12 cases. Thromb Res 2015, 135, 1035–1036.
  41. Delgado MG, Rodríguez S, García R, Sánchez P, Sáiz A, Calleja S: Antiphospholipid syndrome of late onset: A difficult diagnosis of a recurrent embolic stroke. J Stroke Cerebrovasc Dis 2015, 24, 209–211.
  42. Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA: Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: A series of eight cases. Clin Rheumatol 2015, 35, 801–805.
  43. Sciascia S, Breen K, Hunt BJ: Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis. 2015, 26, 476–477.
  44. Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, Sene D, Chaidi RB, Michot JM, Fain O: Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmune Rev 2015, 14, 680–685.
  45. Betancur JF, Bonilla-Abadía F, Hormaza AA, Jaramillo FJ, Cañas CA, Tobón GJ: Direct oral anticoagulants in antiphospholipid syndrome: A real life case series. Lupus 2016, 25, 658–662.
  46. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T: Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2015, 74, 1011–1018.
  47. Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA: RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Hematol 2016, 3, 426–436.
  48. Mani H, Lindhoff-Last E: Main considerable factors for correct laboratory test interpretation under DOA treatment. Thromb J 2013, 1, 11, 22.
  49. Czubek U, Góralczyk T, Zalewski J, Undas A: Monitoring of anticoagulant effects of dabigatran in everyday practice: First experience in 32 Polish patients. Pol Arch Med Wewn 2014, 124, 487–489.
  50. Lippi G, Favaloro EJ: Urgent monitoring of dabigatran plasma levels: Sometimes less is more. Pol Arch Med Wewn 2014, 124, 639–640.
  51. Zalewski J, Undas A: Urgent monitoring of dabigatran plasma levels: Sometimes less is more. Authors’ reply. Pol Arch Med Wewn 2014, 124, 640–641.
  52. Gosselin R, Grant RP, Adcock DM: Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol 2016, 38, 505–513. DOI: 10.1111/ijlh.12528.
  53. Chojnowski K, Górski T, Robak M, Treliński J: Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism. Adv Clin Exp Med 2015, 24, 995–1000.
  54. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL: Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9, 133–139.
  55. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T: Assessment of apixaban plasma levels by laboratory tests: Suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014, 111, 240–248.
  56. Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW: Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost 2014, 12, 1810–1815.
  57. Brunetti L, Bandali F: Dabigatran: Is there a role for coagulation assays in guiding therapy? Ann Pharmacother 2013, 47, 828–840.
  58. Helin TA, Lemponen M, Hjemdahl P, Rönquist-Nii Y, Lassila R, Joutsi-Korhonen L: From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res 2015, 136, 154–160.
  59. Dale BJ, Chan NC, Eikelboom JW: Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016, 172, 315–336.
  60. Dager WE, Gosselin RC, Kitchen S, Dwyre D: Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study. Ann Pharmacother 2012, 46, 1627–1636.
  61. Van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J, Jochmans K, Mullier F, Wijns W, Soumali MR, Coucke W, Vernelen K, Van de Walle P: Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2015, 113, 154–164.
  62. Cuker A, Siegal DM, Crowther MA, Garcia DA: Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014 16, 64, 1128–1139.
  63. Eby C: Novel anticoagulants and laboratory testing. Int J Lab Hematol 2013, 35, 262–268.
  64. Douxfils J, Chatelain B, Chatelain C, Dogné JM, Mullier F: Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost 2016, 115, 368–381.
  65. Kitchen S, Gray E, Mackie I, Baglin T, Makris M; BCSH committee: Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2014, 166, 830–841.
  66. Hillarp A, Gustafsson KM, Faxälv L, Strandberg K, Baghaei F, Fagerberg Blixter I, Berndtsson M, Lindahl TL: Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014, 12, 1545–1553.
  67. Gosselin RC, Adcock DM: The laboratory’s 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016, 14, 886–893.
  68. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S: Performance of coagulation tests in patients on therapeutic doses of dabigatran: A cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013, 11, 1493–1502.
  69. Góralczyk T, Iwaniec T, Wypasek E, Undas A: False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis 2015, 26, 473–475.
  70. Goralczyk T, Wojtowicz K, Undas A: Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: Assessment using Russell viper venom time based assay. Blood Coagul Fibrinolysis 2016 [in press].
  71. Mani H: Interpretation of coagulation test results under direct oral anticoagulants. Int J Lab Hematol 2014, 36, 261–268.
  72. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A: Expert group on coagulation of the external quality assurance in laboratory medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011, 105, 371–378.
  73. Johnson NV, Khor B, Van Cott EM: Advances in laboratory testing for thrombophilia. Am J Hematol 2012, 87, 108–112.
  74. Smock KJ, Plumhoff EA, Meijer P, Hsu P, Zantek ND, Heikal NM, Van Cott EM: Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories. Thromb Haemost 2016, 116, 50–57.
  75. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J: Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016, 41, 206–232.
  76. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W: Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013, 11, 756–760.
  77. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI: Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosistask force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012, 59, 1413–1425.
  78. Mekaj YH, Mekaj AY, Duci SB, Miftari EI: New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 2015, 11, 967–977.